MED8-AS1

Across TCGA pan-cancer cohorts, MED8-AS1 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated MED8-AS1 data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MED8-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED8-AS1 expression acts as an unfavorable survival marker, although some lineages such as PAAD and SKCM show a favorable association.

KIRC, MESO, and LIHC are the cancer types where MED8-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.532	0.707	<.001	130	view →
MESO	DFS	Median	All	0.276	0.440	.002	76	view →
LIHC	DFS	Tertile	All	0.411	0.585	<.001	60	view →
KICH	OS	Median	III,IV	0.468	1.000	.001	58	view →
ACC	DFS	Median	All	0.359	0.739	.001	50	view →
UVM	DFS	Median	III,IV	0.208	0.740	.006	32	view →
BRCA	DFS	Tertile	IV	0.255	0.842	.003	31	view →
PAAD	DFS	Median	II,III,IV	0.476	0.254	<.001	31	view →
LGG	DFS	Median	All	0.317	0.461	<.001	31	view →
KIRP	DFS	Median	III,IV	0.120	0.569	.005	27	view →
PRAD	DFS	Tertile	All	0.696	0.864	<.001	26	view →
THCA	OS	Median	II,III,IV	0.955	0.996	.003	25	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

MED8-AS1–KIRC (DFS)

Open the KIRC breakdown →